Releases
- AKA Announcement on Leadership Change- April 17, 2020
- Risk of Death Associated with Kratom Use Compared to Opioids: Key Points by the Authors Document- November 8th, 2019
- Risk of Death Associated with Kratom Use Compared to Opioids: Key Points by the Authors Document- November 8th, 2019
- AKA Response to St. Charles County, MO Executive- September 19, 2019
- Review of Eggleston et al. 2019 brief report - July 16, 2019
- Updated Kratom Population- June 2019
- CSI - BIA - Controlled Substance Scheduling Comments- April 19, 2019
-
Reply to the CDC: Unintentional Drug Overdose Deaths with Kratom Detected- April 18, 2019
View webinar held with the authors of the report: WEBINAR
American Kratom Association Consumer Alert on Adulterated Kratom Products- April 11, 2019
- American Kratom Association Chairman Challenges Misleading Claims by FDA Commissioner —February 27, 2019
- FDA Fails To Provide Credible Data And Science To Justify Scheduling Kratom —December 20, 2018
- Leading Scientists Strongly Reject FDA 8-Factor Analysis of Kratom—November 28, 2018
- AKA Announces GMP Standards for Vendors—November 20, 2018
- Kratom Advocates Reach Out To Congress—October 29, 2018
- American Kratom Association Petitions Ohio State Board Of Pharmacy—October 19, 2018
- Ohio Board of Pharmacy Recommends Ban on Kratom —October 1, 2018
- FDA Death Data Linked to Adulterated Products—September 24, 2018
- AKA Asks NIDA to Follow the Science—July 31, 2018
- NIDA Affirms Kratom Not Associated with Fatal Overdoses—July 30, 2018
- AKA Announces GMP Standards—July 18, 2018
- AKA and Scientists Author New Letter—June 21, 2018
- Science at Odds with FDA Claim—June 17, 2018
- Inaugural Kratom Leadership Summit—May 2, 2018
- Hogan Lovells Issues "Letter of Concern" To FDA—April 26, 2018
- Molecular Biologist Disproves FDA Claims—March 6, 2018
- Open Letter to the FDA —February 27, 2018
- AKA Issues Requests FDA to End Attacks on Kratom—February 27, 2018
- AKA Addresses CDC Salmonella Report, FDA Release—February 22, 2018
- AKA Encourages Consumer Caution
- AKA Releases Statement on Principles
- AKA Supports FDA Regulation on Impermissible Claims